The Vietnam Cardiac PoC Testing Devices Market was valued at USD 10.55 Million in 2025 and is projected to reach USD 16.69 Million by 2034, growing at a CAGR of 5.23% during the forecast period 2026-2034. The market's growth is driven by government healthcare reforms, investments to modernize medical infrastructure, rising cardiovascular health awareness, and increasing demand for rapid diagnostics. Integration of advanced digital health solutions and AI enhances diagnostic accuracy and clinical decision-making, boosting market expansion.

Study Assumption Years

• Base Year: 2025

• Historical Period: 2020-2025

• Forecast Period: 2026-2034

Vietnam Cardiac PoC Testing Devices Market Key Takeaways

• The market size was USD 10.55 Million in 2025, with a CAGR of 5.23% forecasted from 2026 to 2034.

• Cardiac markers test dominated the product type segment, owning 63% market share in 2025 due to its high specificity in detecting myocardial injury and common use for acute coronary syndrome diagnosis.

• Hospitals led the end-user segment with a 55% market share in 2025, benefiting from advanced infrastructure and substantial diagnostic technology investments.

• The market exhibits moderate competitive intensity, involving multinational diagnostic corporations and regional manufacturers focusing on technological innovations and distribution expansion.

• The Vietnam digital health market is expanding rapidly, expected to grow from USD 2.5 Billion in 2024 to USD 9.5 Billion by 2033 at a CAGR of 14.5%.

Sample Request Link: https://www.imarcgroup.com/vietnam-cardiac-poc-testing-devices-market/requestsample

Market Growth Factors

Rising Prevalence of Cardiovascular Diseases

Cardiovascular diseases remain the leading cause of mortality in Vietnam, fueling demand for fast and accurate diagnostics. Urbanization-related lifestyle changes such as sedentary habits, poor diets, and stress contribute to increased incidences of cardiac conditions across all age groups. The prevalence of hypertension, diabetes, and obesity further exacerbates cardiovascular risks. Healthcare providers emphasize early detection and continuous monitoring, driving sustained investments in point-of-care testing facilities throughout hospitals and clinics nationally.

Government Healthcare Investment and Infrastructure Development

The Vietnamese government is actively modernizing healthcare infrastructure, allocating significant budgets for medical facility upgrades. National equipment upgrade strategies aim to enhance local diagnostic capabilities and decrease reliance on foreign healthcare services. For example, in June 2024, the Ministry of Health approved a program addressing prevention, early detection, and management of non-communicable and mental health diseases through 2025. Healthcare master plans include expanding hospital bed capacities, enhancing medical personnel ratios, and improving healthcare access across all provinces. These initiatives enable public hospitals to procure advanced diagnostic devices while encouraging private sector healthcare investments.

Technological Advancements in Diagnostic Testing

Cardiac biomarker testing technologies are advancing rapidly, extending clinical uses and improving accuracy. High-sensitivity assays facilitate detection of cardiac events at much earlier stages and lower biomarker concentrations than traditional tests, enabling timely interventions. Integration of artificial intelligence and machine learning enhances diagnostic interpretation, reduces uncertainty, and supports clinical decision-making. Connected devices with cloud analytics provide real-time data sharing and trend tracking, bolstering telemedicine applications and population health management. These innovations are increasing the accuracy, accessibility, and cost-effectiveness of point-of-care cardiac testing for providers.

Market Segmentation

Product Type:

• Cardiac Markers Test: Dominates with 63% market share in 2025. These tests are essential in point-of-care cardiac diagnostics due to their high sensitivity and specificity in identifying myocardial injury. They enable quick detection of acute coronary syndromes and myocardial infarctions, facilitating prompt clinical action. High-sensitivity troponin assays and multiplex biomarker platforms are increasingly adopted for comprehensive diagnostic profiling.

• Cardiac Troponin (cTn) Test

• Myoglobin Test

• Creatine Kinase MB Isoenzyme (CK-MB) Test*

• Combinational Test Kits

• Brain Natriuretic Peptide (BNP) Test

• Analyzers

End User:

• Hospitals: Lead with 55% market share in 2025, due to their advanced infrastructure and high patient throughput requiring rapid cardiac assessments. Departments like emergency and intensive care benefit from immediate biomarker results that speed up clinical decisions. Major hospital networks integrate advanced cardiac monitoring as part of digital transformation. Private urban hospitals adopt cutting-edge diagnostics attracting premium care seekers. Government hospitals upgrade diagnostics through modernization programs.

• Diagnostic Laboratories

• Others

Regional Insights

Northern Vietnam dominates with rising demand driven by increasing cardiovascular disease prevalence and healthcare awareness, especially in Hanoi and adjacent provinces. Expansion of urban hospitals and diagnostic centers and government-backed early detection initiatives boost point-of-care device adoption. Increased disposable income and patient preference for rapid diagnostic services are accelerating growth in clinics and hospitals across the region.

Key Players

• Multinational diagnostic corporations

• Regional manufacturers

Recent Developments & News

In September 2025, South Korea's TR Group, supported by FPT Corporation, donated an AI-enabled smart Spirokit device for pulmonary function testing to Lam Dong General Hospital and Hue University of Medicine and Pharmacy. This initiative included free screening for chronic obstructive pulmonary disease (COPD) benefiting over 700 residents. It marked the beginning of cooperative activities between FPT, TR, and Vietnamese hospitals under a joint agreement.

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302